<DOC>
	<DOCNO>NCT00822393</DOCNO>
	<brief_summary>This randomized allogeneic transplantation protocol compare i.v . Treosulfan-based conditioning therapy reduce intensity i.v . Busulfan-based conditioning adult AML MDS patient increase risk standard conditioning therapy . The protocol base result previous phase I/II trial evaluate Treosulfan/Fludarabine condition prior allogeneic haematopoietic stem cell transplantation . The reference arm ( reduced intensity i.v . Busulfan/Fludarabine ) consider accepted medical practice study patient population .</brief_summary>
	<brief_title>Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning ( RIC )</brief_title>
	<detailed_description>To compare efficacy safety Treosulfan-based conditioning ( test ) i.v . Busulfan-based reduced intensity conditioning ( reference ) . The statistical aim study show non-inferiority respect : Event-free survival ( EFS ) within 2 year transplantation . Events define relapse disease , graft failure death ( whatever occurs first ) . 1 . Comparative evaluation incidence CTC grade III/IV mucositis/stomatitis day -6 day +28 2 . Comparative evaluation overall survival ( OS ) cumulative incidence relapse ( RI ) well non-relapse mortality ( NRM ) transplantation-related mortality ( TRM ) within 2 year transplantation 3 . Comparative evaluation day +28 conditional cumulative incidence engraftment 4 . Comparative evaluation day +28 day +100 incidence complete donor-type chimerism 5 . Comparative evaluation cumulative incidence acute chronic GvHD within 2 year transplantation 6 . Comparative evaluation incidence CTC grade III/IV adverse event day -6 day +28 Individual patient followed-up 2 year transplantation . Three confirmatory interim evaluation one final analysis plan , allow stop trial soon question non-inferiority answer ( outline ) . In addition , post-surveillance respect OS EFS conduct one year transplantation last randomised patient .</detailed_description>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>1 . Patients acute myeloid leukaemia acc . WHO , 2008 ( AML complete remission transplant , i.e . blast count &lt; 5 % bone marrow ) myelodysplastic syndrome acc . WHO , 2008 ( MDS blast count &lt; 20 % bone marrow disease history ) indicate allogeneic haematopoietic progenitor cell transplantation consider increase risk standard conditioning therapy accord follow criterion : patient age ≥ 50 year transplant / patient HCTCI score &gt; 2 [ acc . Sorror et al. , 2005 ] 2 . Availability HLAidentical sibling donor ( MRD ) HLAidentical unrelated donor ( MUD ) . Donor selection base molecular high resolution typing ( 4 digit ) class II alleles DRB1 DQB1 gene locus molecular ( least ) low resolution typing ( 2 digit ) class I alleles ( i.e. , antigen ) HLA A , B , C gene locus . In case , class I class II completely identical donor ( 10 10 gene locus ) identify , one antigen disparity ( class I ) and/or one allele disparity ( class II ) patient donor acceptable . Conversely , disparity two antigen ( irrespective involve gene locus ) accept . These definition require degree histocompatibility apply selection relate well unrelated donor . 3 . Adult patient gender , age 18 70 year 4 . Karnofsky Index ≥ 60 % 5 . Written inform consent 6 . Men capable reproduction woman childbearing potential must willing consent use highly effective method birth control condom , implant , injectables , combine oral contraceptive , IUDs , sexual abstinence vasectomise partner treatment least 6 month thereafter 1 . Patients acute promyelocytic leukaemia ( 15 ; 17 ) ( q22 ; q12 ) CR1 2 . Patients consider contraindicated allogeneic HSCT due severe concomitant illness ( within three week prior schedule day 6 ) : patient severe renal impairment like patient dialysis prior renal transplantation Screatinine &gt; 3.0 x ULN calculate creatinineclearance &lt; 60 ml/min patient severe pulmonary impairment , DLCOsb ( Hbadjusted ) /or FEV1 &lt; 50 % severe dyspnoea rest require oxygen supply patient severe cardiac impairment diagnose echocardiography LVEF &lt; 40 % patient severe hepatic impairment indicate hyperbilirubinaemia &gt; 3 x ULN ALT / AST &gt; 5 x ULN 3 . Active malignant involvement CNS 4 . HIVpositivity , active noncontrolled infectious disease treatment ( decrease CRP PCT ) include active viral liver infection 5 . Previous allogeneic HSCT 6 . Pleural effusion ascites &gt; 1.0 L 7 . Pregnancy lactation 8 . Known hypersensitivity treosulfan , busulfan and/or related ingredient 9 . Participation another experimental drug trial within 4 week prior day 6 protocol 10 . Noncooperative behaviour noncompliance 11 . Psychiatric disease condition might compromise ability give informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Treosulfan</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Conditioning</keyword>
	<keyword>Allogeneic</keyword>
	<keyword>Transplantation</keyword>
</DOC>